Article
Immunology
Yu Fu, Weichen Duan, Ran Xu, Jiajia Chen
Summary: This study presents a case of stage IIIC NSCLC achieving a pathological complete response (pCR) following conversion therapy with immunotherapy plus chemotherapy, suggesting the potential efficacy of this treatment approach for a subset of unresectable stage IIIC NSCLC patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Song Guan, Shufeng Zhang, Kai Ren, Xingyue Li, Xue Li, Lujun Zhao
Summary: This study retrospectively analyzed the efficacy and safety of induction chemoimmunotherapy in patients with unresectable stage III non-small cell lung cancer (NSCLC) receiving chemoradiotherapy (CRT). The study found that induction chemoimmunotherapy improved progression-free survival and showed better treatment response and survival outcomes in patients receiving concurrent chemoradiotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Huici Jiang, Dongxuan Shao, Peiyu Zhao, Yupeng Wu
Summary: The receipt of chemotherapy had significantly different effects on cancer-specific mortality in stage II adenocarcinoma and signet-ring cell carcinoma, with decreased risk in AD and increased risk in SRCC. In stage III, both AD and SRCC showed decreased risk with chemotherapy. The study concluded that chemotherapy should not be treated in stage II SRCC, while stage III SRCC should be treated with chemotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Yuchen Li, Rosalyn Anne Juergens, Christian Finley, Anand Swaminath
Summary: For the past two decades, treatment options for stage III NSCLC patients have been limited. However, in the past five years, there have been innovations in biomarker testing, novel therapeutics, precision surgery, and radiotherapy, leading to more personalized treatment options. This review article focuses on completed and ongoing initiatives for the treatment of stage III NSCLC patients.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Linjie Zhang, Yuxiang Deng, Songran Liu, Weili Zhang, Zhigang Hong, Zhenhai Lu, Zhizhong Pan, Xiaojun Wu, Jianhong Peng
Summary: This study aimed to confirm the prognostic value of lymphovascular invasion (LVI) and perineural invasion (PNI) in stage III colon cancer patients and identify patients who could benefit from a complete duration of adjuvant chemotherapy. The results showed that LVI has better prognostic value in stage III colon cancer patients, while PNI only predicts 3-year disease-free survival without significant impact on 3-year overall survival. Furthermore, LVI is also an effective indicator for adjuvant chemotherapy duration.
Article
Oncology
Yosuke Kano, Manabu Ohashi, Yusuke Muneoka, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi, Satoshi Ida, Koshi Kumagai, Rie Makuuchi, Takeshi Sano, Souya Nunobe
Summary: The study found that the risk factors for peritoneal, hematogenous, and lymph nodal recurrence in patients with pStage II or III gastric cancer who completed adjuvant S-1 monotherapy differ. This information may help in the surveillance of recurrence and in developing novel perioperative chemotherapy.
Article
Oncology
Xiaoqin Yin, Jian Li, Bei Chen, Kehuang Liu, Shuo Hu
Summary: This study aims to investigate the combination of inflammatory biomarkers and metabolic parameters of F-18-FDG PET/CT for predicting the major pathological reactions (MPR) in resectable NSCLC patients after neoadjuvant immunochemotherapy, and identify patients who may benefit from the neoadjuvant therapy.
Article
Medicine, Research & Experimental
Wei Nie, Guangyu Tao, Zhenghai Lu, Jie Qian, Yaqiong Ge, Shuyuan Wang, Xueyan Zhang, Hua Zhong, Hong Yu
Summary: This study aimed to develop and validate a radiomic signature for predicting overall survival and candidacy for adjuvant chemotherapy in stage I lung adenocarcinoma patients. The results demonstrated that the radiomic signature was associated with overall survival and could predict the benefit of adjuvant chemotherapy, especially in stage IB patients.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Ranee Mehra, Candice Yong, Brian Seal, Marjolijn van Keep, Angie Raad, Yiduo Zhang
Summary: Durvalumab was found to be cost-effective compared with cCRT alone in patients with unresectable stage III NSCLC in a US healthcare setting, with incremental cost-effectiveness ratios indicating it was below the willingness-to-pay threshold. Sensitivity and scenario analyses highlighted variables affecting the model, but overall the adoption of Durvalumab following cCRT as the new standard of care was supported.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Surgery
Yuanshan Yao, Dongfang Tang, Wen Gao, Huibiao Zhang
Summary: The study aimed to assess the efficacy and safety of neoadjuvant immuno-chemotherapy for resectable stage III NSCLC. The results demonstrated that neoadjuvant immuno-chemotherapy is effective and relatively safe for patients with stage III primary NSCLC.
FRONTIERS IN SURGERY
(2022)
Article
Oncology
Peng Zheng, Yang Lv, Yihao Mao, Feifan Shen, Zhiyuan Zhang, Jiang Chang, Shanchao Yu, Meiling Ji, Qingyang Feng, Jianmin Xu
Summary: This study evaluated the clinical implications of CUL9 expression in colon cancer patients, particularly its prognostic and predictive value for postoperative adjuvant chemotherapy. The results showed that high CUL9 expression was an independent prognostic factor for survival outcomes and could help identify high-risk patients who would benefit from standard 6-month chemotherapy regimens.
Article
Multidisciplinary Sciences
Ailin Qu, Qian Wang, Qing Chang, Jingkang Liu, Yongmei Yang, Xin Zhang, Yanli Zhang, Xiaoshi Zhang, Hongchun Wang, Yi Zhang
Summary: By analyzing tissue samples from stage II colon cancer patients, we developed a predictive model based on long non-coding RNA (lncRNA) to improve the accuracy of prognosis prediction. This model consists of 11 lncRNAs and can categorize patients into high-risk and low-risk groups. It has independent predictive value and stronger prognostic ability compared to current clinical risk factors. The model can facilitate personalized treatment decisions and postoperative counseling, ultimately leading to improved survival.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Arani Sathiyapalan, Ziad Baloush, Peter M. Ellis
Summary: Recent advances in curative intent therapy for stage III NSCLC have shown significant improvements in disease-free survival and overall survival. Adjuvant atezolizumab or pembrolizumab following chemotherapy have been found effective for resectable NSCLC patients. Adjuvant osimertinib therapy has shown significant improvements in both DFS and OS for patients with EGFR gene mutation. Neoadjuvant or perioperative chemotherapy plus immunotherapy have demonstrated significant improvements in pathologic complete response and event-free survival.
Article
Medicine, General & Internal
Aihong Bi, Sifu Yang, Yang Ding, Yong Yu, Wenming Zhan, Tao Song
Summary: This study investigates the prognostic value of radiotherapy (RT) and chemotherapy (CT) in the management of Merkel cell carcinoma (MCC) patients. The results show that RT is associated with significantly improved overall survival (OS), while CT negatively impacts OS. However, in stage III patients, RT is still a positive factor, and CT is not significantly associated with OS.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Corinne Faivre-Finn, David R. Spigel, Suresh Senan, Corey Langer, Bradford A. Perez, Mustafa Ozguroglu, Davey Daniel, Augusto Villegas, David Vicente, Rina Hui, Shuji Murakami, Luis Paz-Ares, Helen Broadhurst, Catherine Wadsworth, Phillip A. Dennis, Scott J. Antonia
Summary: The PACIFIC trial showed that durvalumab improves PFS and OS in Stage III NSCLC patients, regardless of their response to prior CRT. However, in some subgroups, such as patients who received induction chemotherapy, the impact of durvalumab on OS may be limited.